Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss

ABSTRACT Somatic retinoblastoma 1 (RB1) loss is prevalent across different cancer types and is enriched in treatment‐refractory tumors, such as castration‐resistant prostate cancer (CRPC) and small‐cell lung cancer, but cannot be considered as a direct druggable target. In this study, we revealed th...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Tao Zhou, Huayun Yan, Dandan Yin, Yun Deng, Huancheng Fu, Zichen Zhao, Shuang Li, Xiaoxi Lu, Yiqi Deng, Hai‐Ning Chen, Wei‐Han Zhang, Yunying Shi, Yangjuan Bai, Bei Cai, Lanlan Wang, Zhaoqian Liu, Wei Zhang, Lili Jiang, Yang Shu, Bo Liu, Yan Zhang, Heng Xu
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	Wiley 2025-09-01
Sraith:	MedComm
Ábhair:	collateral lethality copy number deletion drug repurposing mercaptopurine NUDT15 RB1
Rochtain ar líne:	https://doi.org/10.1002/mco2.70361
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss

Míreanna comhchosúla